Deutsch English Français

Contact

EP1114644

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1114644

EP1114644 - Composition comprising NPH insulin (neutral protamine hagedorn insulin) [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 20.06.2003 Database last updated on 07.10.2024
Most recent event Tooltip	15.08.2008	Change - representative	published on 17.09.2008 [2008/38]
Applicant(s)	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US
	[N/P]
Former [2001/28]	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US
Inventor(s)	01 / CLARK, Ross, G. 25 Glen Road Devonport, Auckland 9 / NZ
	02 / OESWEIN, James, Q. 514 Sierra Street, PO Box 13 Moss Beach, CA 94038 / US
	03 / YEUNG, Douglas, A. 2628 Benchark Avenue Fremont, CA 94536 / US
	[2002/29]
Former [2002/27]	01 / CLARK, Ross, G. 25 Glen Road Devonport, Auckland 9 / NZ
	02 / OESEIN, James, Q. 514 Sierra Street, PO Box 13 Moss Beach, CA 94038 / US
	03 / YEUNG, Douglas, A. 2628 Benchark Avenue Fremont, CA 94536 / US
Former [2001/35]	01 / CLARK, Ross, G. 25 Glen Road Devonport, Auckland 9 / NZ
	02 / OESEIN, James, Q. 123 Madrone Avenue Half Moon Bay, CA 94018 / US
	03 / YEUNG, Douglas, A. 2628 Benchark Avenue Fremont, CA 94536 / US
Former [2001/28]	01 / CLARK, Ross, G. 711 Ursula Avenue Pacifica, CA 94044 / US
	02 / OESEIN, James, Q. 123 Madrone Avenue Half Moon Bay, CA 94018 / US
	03 / YEUNG, Douglas, A. 2628 Benchark Avenue Fremont, CA 94536 / US
Representative(s)	Wichmann, Hendrik, et al Patentanwälte Isenbruck Bösl Hörschler PartG mbB Prinzregentenstrasse 68 81675 München / DE
	[N/P]
Former [2008/38]	Wichmann, Hendrik, et al Isenbruck Bösl Hörschler Wichmann Huhn Patentanwälte Prinzregentenstrasse 68 81675 München / DE
Former [2003/12]	Wichmann, Hendrik, Dr., et al Patentanwälte Isenbruck Bösl Hörschler Wichmann Huhn Postfach 86 08 80 81635 München / DE
Former [2001/28]	Dost, Wolfgang, Dr.rer.nat., Dipl.-Chem., et al Patent- und Rechtsanwälte Bardehle . Pagenberg . Dost . Altenburg . Geissler . Isenbruck Galileiplatz 1 81679 München / DE
Application number, filing date	01106315.3	31.07.1997
	[2001/28]
Priority number, date	US19960696314	13.08.1996 Original published format: US 696314
	[2001/28]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP1114644
	Date:	11.07.2001
	Language:	EN
	[2001/28]
	Type:	B1 Patent specification
	No.:	EP1114644
	Date:	14.08.2002
	Language:	EN
	[2002/33]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	18.05.2001
Classification	IPC:	A61K38/28, A61P3/10	[2002/03]
	CPC:	A61K9/0019 (EP,US); A61K38/30 (EP,US); A61K47/12 (EP,US); A61P3/10 (EP); A61K47/02 (EP,US); A61K47/10 (EP,US)
	C-Set:	A61K38/30, A61K2300/00 (EP,US)
	Former IPC [2001/28]	A61K38/30, // (A61K38/30, 38:28)
Designated contracting states	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2002/33]
Former [2001/28]	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
Extension states	AL	15.03.2001
	LT	15.03.2001
	LV	15.03.2001
	RO	15.03.2001
	SI	15.03.2001
Title	German:	Zusammensetzung die NPH-Insulin (Neutral-protamin Hagedorn Insulin) enthält	[2001/28]
	English:	Composition comprising NPH insulin (neutral protamine hagedorn insulin)	[2001/28]
	French:	Composition comportant NPH insuline (insuline protamine neutre de Hagedorn)	[2002/05]
	Former [2001/28]	Composition comportant NPH insuline (neutre protamine insuline de Hagedorn)
Examination procedure	04.05.2001	Examination requested [2001/28]
	04.05.2001	Request for accelerated examination filed
	25.06.2001	Despatch of a communication from the examining division (Time limit: M06)
	25.06.2001	Decision about request for accelerated examination - accepted: Yes
	13.11.2001	Reply to a communication from the examining division
	03.01.2002	Despatch of communication of intention to grant (Approval: No)
	10.05.2002	Despatch of communication of intention to grant (Approval: later approval)
	10.05.2002	Fee for grant paid
	10.05.2002	Fee for publishing/printing paid
	31.05.2002	Communication of intention to grant the patent
Parent application(s) Tooltip	EP97935259.8 / EP0918536
Opposition(s)	15.05.2003	No opposition filed within time limit [2003/32]
Fees paid	Renewal fee
	15.03.2001	Renewal fee patent year 03
	15.03.2001	Renewal fee patent year 04
	15.03.2001	Renewal fee patent year 05
	05.06.2002	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]EP0331630 (CIBA GEIGY AG [CH]) [X] 6 * abstract * * page 2, lines 40-65 - page 3, lines 10-30; example 2; claims 1,4,5,7,10 * * claims 19-21 *;
		[X]EP0561330 (LIEDTKE PHARMED GMBH [DE]) [X] 6 * abstract * * column 8 *;
		[X]WO9601125 (PHARMACIA AB [SE], et al) [X] 6 * abstract *;
		[X]WO9602270 (GROPEP PTY LTD [AU], et al) [X] 6 * abstract * * page 7, lines 18-31; example 1; claims 1,3,4 * * claim 16 *;
		[E]WO9934822 (AMYLIN PHARMACEUTICALS INC [US]) [E] 1-6 * abstract ** page 24; examples 3,4 *;
		[E]WO0023098 (NOVO NORDISK AS [DK]) [E] 1-6 * table 3 *;
		[E]WO0061177 (GENENTECH INC [US]) [E] 1-6 * example 1 *;
		[E]WO0100223 (MINIMED INC [US]) [E] 6 * abstract *;
		[X] - QUATTRIN T. ET AL, "Dual hormonal replacement with insulin and recombinant human insulin- like growth factor I in IDDM: Effects on glycemic control, IGF-I levels, and safety profile", DIABETES CARE, 1997, 20/3 (374-380), USA, XP002045791 [X] 6 * abstract * * page 375, column 2, paragraph 2 - page 376, column 1, paragraph 1 * * page 377, column 2, paragraph 2 *
		[X] - JABRI N. ET AL, "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients", DIABETES, 1994, 43/3 (369-374), USA, XP002045793 [X] 6 * abstract * * page 370, column 1, paragraph 2 * * page 370, column 1, paragraph 3 - column 2, paragraph 2 * * table 4 * DOI: http://dx.doi.org/10.2337/diabetes.43.3.369

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p